51 results about "Diosgenin" patented technology

The invention provides a preparation method of a polygonatum sibiricum fermentation product, which comprises the following steps: A) pretreating a polygonatum sibiricum raw material, and mixing with water to obtain polygonatum sibiricum slurry; b) heating the polygonatum sibiricum slurry, mixing the heated polygonatum sibiricum slurry with a nitrogen source and a phosphorus source, and performing primary sterilization to obtain sterilized polygonatum sibiricum slurry; c) inoculating the sterilized rhizoma polygonati slurry with saccharomycetes, and fermenting to obtain fermentation liquor; d) adding a carbon source into the fermentation liquor, performing secondary sterilization, inoculating lactic acid bacteria, performing secondary fermentation, and performing third sterilization to obtain secondary fermentation liquor; and E) adding a compound enzyme into the secondary fermentation liquid for enzymolysis, then sterilizing for four times, and centrifuging to obtain the polygonatum sibiricum fermentation product. 3000 Da), a small molecule polypeptide (lt; the polygonatum kingianum fermentation product prepared by the method disclosed by the invention has the advantages that the conversion of polygonatum kingianum saponin can be promoted, the contents of diosgenin and trilliin are increased and calibrated, and the polygonatum kingianum fermentation product has the effects of improving the reaction capability and the exercise capability.

The invention belongs to the technical field of forest medicine cultivation, and particularly relates to a multi-element efficient forest medicine cultivation method which comprises the following steps: S1, selecting a low-hill pest-free pine forest; s2, caulis spatholobi is cultivated close to the root of the pine forest; s3, a plurality of soil slopes are leveled in the open field of the pine forest in a layered mode, and fructus amomi and yellow ginger are planted on the soil slopes in a crossed mode; in the cultivation process, organic fertilizer is applied to the roots of the caulis spatholobi, the fructus amomi and the yellow ginger in a hole mode. According to the multi-element efficient cultivation method for the forest medicine, the organic fertilizer with the mixture of acinetobacter peteri, bacillus cereus and aspergillus clavatum as the fermentation inoculant is applied in the process of cultivating caulis spatholobi, fructus amomi and yellow ginger, so that the yield of the yellow ginger is increased, and meanwhile, the content of diosgenin in the yellow ginger can be increased; the method has very important significance for improving the quality of the yellow ginger in multi-element efficient cultivation of forest medicines.

The invention discloses a diosgenin derivative containing a 1, 2, 3-triazole structure fragment as well as a preparation method and application of the diosgenin derivative, and belongs to the field of natural medicinal chemistry and medicinal chemistry. Based on a molecular heterozygosis principle, diosgenin is used as a lead compound and is heterozygous with a 1, 2, 3-triazole structure fragment with different substituent groups to obtain a derivative shown as a general formula (I) or (I). The diosgenin derivative containing the 1, 2, 3-triazole fragment, disclosed by the invention, has good anti-breast cancer activity. Pharmacological experiment results show that the anti-tumor activity of part of the derivatives on human breast cancer cells is obviously superior to that of diosgenin, and the toxicity on human normal gastric mucosa epithelial cells is relatively small, so that the derivatives are expected to be further developed into anti-tumor drugs. # imgabs0 #

The invention discloses a series of recombinant bacteria for expressing a steroid compound taking a cyclopentane multi-hydrogen phenanthrene structure as a structural mother nucleus, such as recombinant strains for expressing cholesterol, 22-hydroxycholesterol, diosgenin or polyphyllin II, and construction and application of the strains. The invention provides a recombinant bacterium which can efficiently express a steroid compound taking cyclopentane multi-hydrogen phenanthrene as a structural mother nucleus, for example, the yield of diosgenin can be increased to the level of 40 mg / L or above, heterologous synthesis of the polyphyllin II is also realized to obtain a polyphyllin II synthetic strain, the yield of the polyphyllin II in a shake flask reaches 0.13 mg / L, and the yield of the polyphyllin II in the shake flask reaches 0.13 mg / L. The strain is the first strain for heterologous synthesis of the polyphyllin II at present.

This invention discloses a acne-repairing and repairing composition specifically developed for adolescents and its application, relating to the field of cosmetic technology. The invention provides an acne-repairing and repairing composition comprising 5-12 parts of guaiac extract, 1-6 parts of eggplant extract, 0.001-0.01 parts of aescin, 0.01-0.1 parts of diosgenin, and 0.01-0.1 parts of asiaticoside. This invention achieves a three-dimensional synergistic effect of "anti-inflammatory, repair, and metabolic regulation" through the synergistic interaction of five components: guaiac extract, eggplant extract, aescin, diosgenin, and asiaticoside, forming a comprehensive management system for acne and post-acne repair in adolescents.

To provide a composition with effects in enhancing muscle strength and motor function.SOLUTION: A composition comprises a processed plant material comprising diosgenin and 3-hydroxyisovaleric acid or a salt thereof, or derivatives thereof.SELECTED DRAWING: Figure 2

The present invention belongs to the technical field of plant growth regulators. More specifically, the present invention provides a composite plant growth regulator for tea tree cuttings, comprising a composition A and a composition B used separately; the composition A comprises ascorbic acid, brassinolide, indolebutyric acid, eugenol and diosgenin, and the composition B comprises furifrinol, diethylaminoethanol hexanoate, aluminum sulfate, ammonium dihydrogen phosphate and zinc sulfate. The composite plant growth regulator of the present invention effectively reduces the formation of non-rooting callus at the base of the cuttings, and significantly increases the number and length of adventitious roots. In addition, the present invention can not only significantly improve the number and quality of the root system of the cuttings, improve the rooting rate of the cuttings, but also effectively reduce the cost of tea tree seedling cultivation, greatly reduce the loss and cycle of tea tree seedling cultivation, and provide strong technical support for the large-scale cutting propagation of difficult-to-root tea trees, and has good application prospects and value.

The invention belongs to the technical field of medicines, and particularly relates to application of dioscin combined with chidamide in diffuse large B-cell lymphoma. Specifically, research finds that the dioscin can significantly inhibit DLBCL cell proliferation and induce cell cycle arrest and apoptosis by up-regulating PINK1 / Parkin mediated mitochondrial autophagy and enhancing H3K27 acetylation mediated epigenetic regulation. When the chidamide and the dioscin are combined for use, a synergistic effect can be generated, and by further increasing the H3K27ac level, the cell apoptosis induction effect is enhanced, and the in-vivo and in-vitro anti-tumor activity on DLBCL is remarkably improved. The invention provides a novel and efficient DLBCL combined treatment scheme, and provides a new pharmaceutical composition and theoretical support for clinical diagnosis and treatment of DLBCL, so that the application has good practical application value.

The present application relates to the technical field of biotechnology, and discloses a C26 hydroxylase for improving the biosynthesis efficiency of diosgenin, a coding gene, a preparation method and an application. The protein of the C26 hydroxylase is any one of the following a), b) or c): a) a protein with an amino acid sequence shown in SEQ ID NO. 2; b) a fusion protein obtained by connecting a tag to the N terminal and / or C terminal of the protein shown in SEQ ID NO. 2; and c) a protein with the same function obtained by substitution, deletion and / or addition of one or more amino acid residues to the amino acid sequence shown in SEQ ID NO. 2. The C26 hydroxylase provided by the present application can improve the biosynthesis efficiency of diosgenin, and provides a key gene resource for producing diosgenin by using an enzyme method.

The invention discloses a glycosyl hydrolase derived from intestinal bacteria and application of the glycosyl hydrolase. A glycosyl hydrolase gene for catalyzing trillioside to be hydrolyzed into diosgenin is cloned from intestinal microorganism enterococcus faecalis for the first time, and protein coded by the glycosyl hydrolase gene is identified as multifunctional glycosyl hydrolase; the diosgenin can be catalyzed to generate diosgenin, and the hydrolysis of other saponins such as steroid saponin and C3, C6 and C21 glycosyl of ginsenoside can be catalyzed, so that a basis is provided for the biological enzymolysis of the diosgenin and other saponins or sapogenin. Meanwhile, biological enzymolysis of the diosgenin makes up for the defects of high production cost, serious environmental pollution and the like of a traditional acid hydrolysis method, and the diosgenin has a great application prospect.

The invention discloses a niobium-based solid acid catalyst and a method for preparing diosgenin, and the method comprises the following steps: (1) carrying out reflux extraction on yellow ginger powder by using an alcohol solvent I, and drying to obtain crude saponin powder; and (2) reacting a mixture containing the crude saponin powder, a niobium-based solid acid catalyst and an alcohol solvent II in a closed reactor to obtain diosgenin. According to the method, the problems that equipment is easily corroded and wastewater is difficult to treat when homogeneous catalysts such as sulfuric acid and hydrochloric acid are used in a traditional process are solved, and the whole process has higher economic benefits due to recycling of the heterogeneous catalysts.

This invention discloses a biphasic combined Lewis acid hydrolysis method for extracting diosgenin from fenugreek, belonging to the field of natural product extraction technology. The extraction method disclosed in this invention includes: defatting fenugreek raw material, mixing it with a biphasic reaction system composed of Lewis acid, concentrated hydrochloric acid, methanol, water, and petroleum ether, and carrying out a hydrolysis reaction under heating conditions. After the reaction, the organic phase is separated, concentrated, and dried to obtain diosgenin. This invention innovatively introduces a Lewis acid catalyst into the biphasic acid hydrolysis system of fenugreek, achieving significant results such as a 25% reduction in reaction time, a 50% reduction in concentrated hydrochloric acid usage, and a 25% reduction in water usage while ensuring the extraction rate of diosgenin. This method has advantages such as mild conditions, low acid consumption, short processing time, and environmental friendliness, and is suitable for the large-scale green production of diosgenin.

This invention discloses the application of plant extracts in the preparation of drugs that inhibit canine parvovirus, belonging to the field of biomedical technology. The plant extract is at least one selected from phlorizin, neomethylhesperidin-dihydrochalcone, tribulus terrestris saponin, stevia glycoside, soy isoflavones, berberine hydrochloride, diosgenin, and silymarin. Through in-depth research on various plant extracts, this invention has found that phlorizin, neomethylhesperidin-dihydrochalcone, tribulus terrestris saponin, stevia glycoside, soy isoflavones, berberine hydrochloride, diosgenin, and silymarin all exhibit significant inhibitory effects on canine parvovirus, with soy isoflavones showing particularly outstanding effects. This research provides a novel natural drug option for the prevention and treatment of canine parvovirus. This invention not only expands the application scope of natural plant extracts in the veterinary medicine field but also provides important technical support for the development of novel, highly effective, safe, and side-effect-free drug formulations for the prevention and treatment of canine parvovirus.

The application discloses a niobium-based solid acid catalyst and a method for preparing diosgenin, and the method comprises the following steps: (1) extracting yellow ginger powder with alcohol solvent I by refluxing, and drying to obtain crude saponin powder; (2) in a closed reactor, reacting a mixture containing the crude saponin powder, the niobium-based solid acid catalyst and alcohol solvent II to obtain diosgenin. The application solves the problems that in the traditional process, the use of homogeneous catalysts such as sulfuric acid and hydrochloric acid can easily cause corrosion of equipment, and waste water is difficult to treat, and the recycling of the heterogeneous catalyst also makes the whole process have higher economic benefits.

The composition and / or combinations includes diosgenin and at least one other agent selected from vitamin D and α-lactalbumin and its use in the regularization of the menstrual cycle and in the reduction of ovarian cysts, in particular in women affected with polycystic ovarian syndrome (PCOS) phenotype D.

The invention provides a method for preparing 5 alpha-hydroxyl laxogenin by a one-pot method, which comprises the following steps: S1) dissolving diosgenin in a mixture of an organic solvent and water, adding a halogenating reagent, and heating for reaction after dissolving to obtain a dihydroxylation intermediate; s2) adding an oxidizing agent into the reaction liquid obtained in the step S1), adding a quenching agent after reaction, adding a mixture of an organic solvent and water after vacuum concentration, pulping, filtering and drying to obtain a 5 alpha-hydroxyl laxogenin crude product; s3) adding a pulping solvent into the crude product obtained in the step S2), heating, pulping and filtering to obtain a wet product; and adding a recrystallization solvent into the wet product, heating for dissolving, dropwise adding a crystallization solvent for crystallization, carrying out gradient cooling, filtering, and drying to obtain the 5 alpha-hydroxy laxogenin. The method avoids introducing a protecting group, so that the reaction route is greatly shortened; reaction intermediates do not need to be separated and purified, reaction procedures are reduced, and production cost is reduced; the refined finished product is relatively high in purity and stable in quality; the reaction conditions are mild.

The invention relates to the technical field of biology, and discloses C26 hydroxylase for improving the biosynthesis efficiency of diosgenin as well as a coding gene, a preparation method and application of the C26 hydroxylase. The protein of the C26 hydroxylase is any one of the following a) or b) or c): a) a protein with an amino acid sequence as shown in SEQ ID NO.2; b) a fusion protein obtained by connecting a label to the N terminal and / or C terminal of the protein as shown in SEQ ID NO.2; and c) carrying out substitution and / or deletion and / or addition of one or more amino acid residues on the amino acid sequence as shown in SEQ ID NO.2 to obtain the protein with the same function. The C26 hydroxylase provided by the invention can improve the biosynthesis efficiency of the diosgenin, and provides a key gene resource for producing the diosgenin by using an enzymic method.

The invention relates to the technical field of bioengineering, in particular to application of a ZBED1 expression inhibitor in preparation of a medicine for treating cytarabine-resistant leukemia. The invention provides an application of a ZBED1 expression inhibitor in preparation of a drug for treating cytarabine-resistant leukemia. The drug for treating cytarabine-resistant leukemia comprises the ZBED1 expression inhibitor. The key effect of ZBED1 in leukemia drug resistance is determined for the first time, and a traditional Chinese medicine active component diosgenin with a function of selectively inhibiting ZBED1 is found. The component not only can have a synergistic effect with cytarabine to reverse the cytarabine resistance of leukemia, but also provides a new target site and a molecular marker for clinically predicting and improving the treatment effect of a patient. The innovative strategy brings a new hope for treating leukemia, and particularly provides a more effective solution for solving the problem of drug resistance of cytarabine.

The embodiment of the invention discloses a synthesis method of a diosgenin derivative Anzurogenin D. The diosgenin derivative Anzurogenin D is shown in the description. The method comprises the following steps: (1) dropwise adding an oxidizing agent into a system of diosgenin, a catalyst and an organic solvent, continuously reacting after dropwise adding, then adding a quenching agent for quenching reaction, then adding a dispersing solvent and water, filtering and drying to obtain an Anzurogenin D crude product; and (2) carrying out pulping and refining treatment on the Anzurogenin D crude product, so as to obtain an Anzurogenin D finished product. By introducing the transition metal catalyst, the use of a strong oxidant is avoided, so that the reaction conditions are milder and more controllable; the dihydroxylation reaction is completed in one step, the introduction of a protecting group is avoided, and the atom economy of the process is relatively good; the finished product is high in purity and stable in quality; the used raw materials are cheap, easy to obtain and environment-friendly, the whole process is simple and controllable, and the method is suitable for large-scale workshop production.

The application of diosgenin in the preparation of drugs for the prevention or treatment of acute kidney injury falls within the pharmaceutical field. Specifically, this invention discloses that diosgenin, by directly binding to the PIK3CA protein, regulates the PI3K / Akt-NF-κB pathway, inhibiting inflammatory responses, apoptosis, and pyroptosis in renal tubular epithelial cells, thereby alleviating kidney damage. Cellular experiments show that diosgenin at concentrations of 0.1–5 μM can significantly protect renal tubular epithelial cells; animal experiments show that doses of 1–20 mg / kg can significantly improve renal function and reduce pathological damage in mice with acute kidney injury. This invention clarifies a complete chain of evidence from "compound—target—pathway—efficacy," providing a new drug candidate for the treatment of acute kidney injury and offering a paradigm for the mechanistic study of active ingredients in traditional Chinese medicine, contributing to the transformation of traditional Chinese medicine from empirical medicine to evidence-based and molecular medicine.

The invention discloses an acne removing and repairing composition specially researched by teenagers and application of the acne removing and repairing composition, and relates to the technical field of cosmetics. The invention provides an acne removing and repairing composition. The acne removing and repairing composition is prepared from the following components in parts by weight: 5 to 12 parts of guaiacol extract, 1 to 6 parts of solanaceous fruit extract, 0.001 to 0.01 part of escin, 0.01 to 0.1 part of diosgenin and 0.01 to 0.1 part of madecassoside. According to the acne treatment composition disclosed by the invention, the five components including the guaiacol extract, the solanaceous fruit extract, the aescin, the diosgenin and the madecassoside are mutually coordinated, so that three-dimensional coordination of anti-inflammation, repair and metabolic regulation is realized, and full-period management on acnes of teenagers and post-acne repair of the teenagers is formed.

The present invention relates to a composition for use in a method of treating a liver disease, preferably metabolic dysfunction-associated steatohepatitis (MASH). The composition comprises: • An effective amount of at least one saponin active ingredient (preferably ginsenoside or diosgenin) • And / or an effective amount of at least one anthelmintic (preferably niclosamide or nitazoxanide) • And / or an effective amount of at least one mitochondrial uncoupler.

The invention relates to the technical field of medicines, in particular to a pharmaceutical composition for treating diabetic retinopathy, which consists of diosgenin, madecassoside, rutin and betaine. Animal experiments verify that the pharmaceutical composition has a good effect of treating or inhibiting disease development on diabetic retinopathy, can improve subjective symptoms of patients and improve the life quality of the patients, has no toxic or side effect, is not easy to generate tolerance, has great influence on research and treatment of diabetic retinopathy, and can be used for treating diabetic retinopathy and treating diabetic retinopathy and treating diabetic retinopathy and treating diabetic retinopathy and treating diabetic retinopathy and treating diabetic retinopathy. The clinical practical value is realized.

The invention provides a genetic engineering strain for producing a steroid drug intermediate by converting diosgenin as well as a construction method and application of the genetic engineering strain, and belongs to the technical field of biochemical engineering. The method comprises the following steps: carrying out single gene knockout inactivation or combined knockout inactivation on a key gene kstD and / or kshA for degrading a mother nucleus of a steroid compound in a microorganism, a key gene BV-2539 for catalyzing conversion of the steroid compound from C-21 to C-19, and a key negative transcriptional regulation factor IclR-2535; and carrying out single gene overexpression or combined overexpression on key genes kstD2, kshA3, kshA4 and BV-2539 for catalyzing synthesis of a C-19 steroid drug intermediate in a microbial diosgenin pathway, so as to construct a genetic engineering strain. According to the method, the green manufacturing of synthesizing the steroid drug intermediate by converting the diosgenin through the genetic engineering strain is realized for the first time, the production steps of the steroid drug are simplified, the conversion rate of the steroid drug intermediate and the production efficiency of the steroid drug are greatly improved, and the method has good social value and economic value and is beneficial to industrial production.

The present invention discloses a method for simultaneously determining multiple chemical components in Cymbidium heterophyllum, and relates to the technical field of separation and analysis of natural products. Ultra-high performance liquid chromatography is used to simultaneously determine the chemical components of Cymbidium heterophyllum, and the chemical components include at least neochlorogenic acid, cryptochlorogenic acid, and diosgenin-7-O-glucuronide; the detection conditions of ultra-high performance liquid chromatography include: chromatographic column stationary phase: diisobutyl group is bonded to the silica gel surface through siloxane; mobile phase A is selected from methanol or acid-containing methanol, and mobile phase B is selected from water or acid-containing aqueous solution; mobile phase A and mobile phase B are used as a mixed mobile phase for gradient elution. The present invention establishes a UPLC content determination method for multiple chemical components in Cymbidium heterophyllum, which is simple to operate, has reliable results, and good repeatability, and can provide a certain reference for the determination of the content of chemical components in Cymbidium heterophyllum and the improvement of existing quality standards.

This invention belongs to the field of natural product biosynthesis technology, specifically relating to a glycosyltransferase UGT73DY2, its encoding gene, and its applications. The diosgenin-3-O-α-L-pyranorhamnetose-(1→4)-[α-L-pyranorhamnetose]-(1→2)-β-D-glucoside and pennosapogenin-3-O-α-L-pyranorhamnetose-(1→4)-[α-L-pyranorhamnetose]-(1→2)-β-D-glucoside synthesized by the glycosyltransferase UGT73DY2 of this invention are key intermediate compounds in the biosynthesis of Paris polyphylla saponins II or VII. These compounds are synthesized in vitro under the catalytic action of glycosyltransferase UGT73DY2, laying the foundation for the industrial production of Paris polyphylla saponins II and VII. Meanwhile, a new Ophiopogon japonicus saponin compound can also be synthesized under the action of glycosyltransferase UGT73DY2, providing a new direction for further research on the application of glycosyltransferase UGT73DY2.

The invention belongs to the technical field of natural product biosynthesis, and particularly relates to glycosyl transferase UGT73DY2 as well as a coding gene and application thereof. Diosgenin-3-O-alpha-L-rhamnopyranosyl-(1-> 4)-[alpha-L-rhamnopyranosyl]-(1-> 2)-beta-D-glucoside and pennogenin-3-O-alpha-L-rhamnopyranosyl-(1-> 4)-[alpha-L-rhamnopyranosyl]-(1-> 2) synthesized under catalysis of glycosyl transferase UGT73DY2 The-beta-D-glucoside is a key intermediate compound for biosynthesis of the polyphyllin II or the polyphyllin VII, the compounds are catalytically synthesized in vitro under the action of glycosyl transferase UGT73DY2, and a foundation is laid for industrial production of the polyphyllin II and the polyphyllin VII. Meanwhile, a new ophiopogonin compound can be synthesized under the action of the glycosyl transferase UGT73DY2, and a new direction is provided for further application research of the glycosyl transferase UGT73DY2.

The invention provides a non-invasive and natural formulation and a method of producing a formulation comprising an antidiabetic agent diosgenin encapsulated and protected in an oil-in-water nanoemulsion matrix, wherein diosgenin is dissolved in an oil phase of sesame oil and bottle gourd seed oil. The nanoemulsion matrix is prepared using low energy and ambient temperature and includes Tween 80 as a non-ionic surfactant and glycerol as a co-surfactant. The formulation allows for the transdermal delivery of encapsulated diosgenin to a patient for treatment of diabetes, and in particular for Type II diabetes mellitus.

The invention discloses a novel medical application of diosgenin, and relates to an application of diosgenin in preparation of drugs for preventing and / or treating tanshinone addiction withdrawal. According to the method, the influence of the diosgenin on the core behavioral indications of the fluazinone addiction is evaluated through an animal model, wherein the influence comprises fluazinone-induced hypermental movement and a foraging behavior based on condition position preference. The result shows that the diosgenin can obviously inhibit the mental movement activity increase caused by the fluazinone, and can effectively reverse the foraging behavior with preferred conditions and positions. The diosgenin is proved to be capable of relieving the positive strengthening and mental movement stimulation effect of the fluazinone so as to effectively weaken the dependence and the desire on the fluazinone, and can be used for preventing and treating the fluazinone addiction. The invention provides a clear direction and an experimental basis for developing the anti-fluazinone addiction medicine taking the diosgenin as an active component, and has a good clinical application prospect.

The invention discloses a cytochrome P450 monooxygenase PpCYP81BY1, an expression gene, an expression cassette, a recombinant vector, a host bacteria and an application of the above-mentioned cytochrome P450 monooxygenase PpCYP81BY1. In conjunction with a specific embodiment, the cytochrome P450 monooxygenase PpCYP81BY1 of the present invention can catalyze the C-17 hydroxylation reaction of diosgenin, convert it into diosgenin, provide a key element for the synthesis of diosgenin, and can be used for the synthesis of diosgenin saponins. The present invention clones and verifies the key role of Paris polyphylla cytochrome P450 monooxygenase PpCYP81BY1 in the biosynthetic pathway of diosgenin for the first time, and Paris polyphylla cytochrome P450 monooxygenase PpCYP81BY1 has important applications in the biosynthesis field of diosgenin.